CYRANO THERAPEUTICS, INC.

Cyrano Therapeutics Advances Novel Treatment for Post-Viral Smell Loss with Soft Mist Technology

2 months ago

• Cyrano Therapeutics has completed enrollment of 150 patients in its Phase 2 FLAVOR trial evaluating CYR-064, a potential first-in-class treatment for post-viral smell loss, with data expected in Q4 2025. • The company secured an exclusive license agreement with Resyca for soft mist nasal spray technology designed to enhance drug deposition in the olfactory region, potentially improving therapeutic efficacy. • Post-viral hyposmia affects over 60 million people across the US, Europe, and Japan, with no FDA-approved treatments currently available, representing a significant unmet medical need.